Etravirine-d6

Modify Date: 2024-01-14 17:55:14

Etravirine-d6 Structure
Etravirine-d6 structure
Common Name Etravirine-d6
CAS Number 1142096-06-7 Molecular Weight 443.32600
Density N/A Boiling Point N/A
Molecular Formula C20H7BrD8N6O Melting Point N/A
MSDS N/A Flash Point N/A

 Use of Etravirine-d6


Etravirine-d8 (R165335-d8) is the deuterium labeled Etravirine. Etravirine (R165335) is a non-nucleoside reverse transcriptase inhibitor (NNRTI) used for the treatment of HIV[1][2].

 Names

Name 4-[6-amino-5-bromo-2-(4-cyanoanilino)pyrimidin-4-yl]oxy-2,6-dideuterio-3,5-bis(trideuteriomethyl)benzonitrile
Synonym More Synonyms

 Etravirine-d6 Biological Activity

Description Etravirine-d8 (R165335-d8) is the deuterium labeled Etravirine. Etravirine (R165335) is a non-nucleoside reverse transcriptase inhibitor (NNRTI) used for the treatment of HIV[1][2].
Related Catalog
In Vitro Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].
References

[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216.

[2]. Andries, K., et al. TMC125, a novel next-generation nonnucleoside reverse transcriptase inhibitor active against nonnucleoside reverse transcriptase inhibitor-resistant human immunodeficiency virus type 1. Antimicrob Agents Chemother, 2004. 48(12): p. 468

[3]. Lazzarin, A., et al. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet, 2007. 370(9581): p. 39-48.

 Chemical & Physical Properties

Molecular Formula C20H7BrD8N6O
Molecular Weight 443.32600
Exact Mass 442.09900
PSA 120.64000
LogP 5.37156

 Synthetic Route

 Synonyms

Etravirine-d8
TMC 125-d8